Pradelli, L. et al. 2014. Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients. Farmeconomia. Health economics and therapeutic pathways. 15, 4 (Dec. 2014), 101–112. DOI:https://doi.org/10.7175/fe.v15i4.971.